

# Hedwig M Blommestein

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5194047/publications.pdf>

Version: 2024-02-01

25  
papers

311  
citations

840776

11  
h-index

888059

17  
g-index

25  
all docs

25  
docs citations

25  
times ranked

617  
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-term Outcomes in Patients With Multiple Myeloma. <i>HemaSphere</i> , 2018, 2, e45.	2.7	38
2	A cost-effectiveness analysis of real-world treatment for elderly patients with multiple myeloma using a full disease model. <i>European Journal of Haematology</i> , 2016, 96, 198-208.	2.2	33
3	A Practical Guide for Using Registry Data to Inform Decisions About the Cost Effectiveness of New Cancer Drugs: Lessons Learned from the PHAROS Registry. <i>Pharmacoeconomics</i> , 2015, 33, 551-560.	3.3	30
4	Balancing the Optimal and the Feasible: A Practical Guide for Setting Up Patient Registries for the Collection of Real-World Data for Health Care Decision Making Based on Dutch Experiences. <i>Value in Health</i> , 2017, 20, 627-636.	0.3	27
5	Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. <i>Pharmacoeconomics</i> , 2017, 35, 1211-1221.	3.3	21
6	Validity of Surrogate Endpoints and Their Impact on Coverage Recommendations: A Retrospective Analysis across International Health Technology Assessment Agencies. <i>Medical Decision Making</i> , 2021, 41, 439-452.	2.4	21
7	Microcosting Study of Rituximab Subcutaneous Injection Versus Intravenous Infusion. <i>Clinical Therapeutics</i> , 2017, 39, 1221-1232.e4.	2.5	17
8	Stage-specific disease recurrence and survival in localized and regionally advanced cutaneous melanoma. <i>European Journal of Surgical Oncology</i> , 2019, 45, 825-831.	1.0	17
9	Efficacy of first-line treatments for multiple myeloma patients not eligible for stem cell transplantation: a network meta-analysis. <i>Haematologica</i> , 2019, 104, 1026-1035.	3.5	17
10	Cost-effectiveness of rituximab as maintenance treatment for relapsed follicular lymphoma: results of a population-based study. <i>European Journal of Haematology</i> , 2014, 92, 398-406.	2.2	16
11	Do existing real-world data sources generate suitable evidence for the HTA of medical devices in Europe? Mapping and critical appraisal. <i>International Journal of Technology Assessment in Health Care</i> , 2021, 37, e62.	0.5	14
12	Cost-effectiveness of obinutuzumab for chronic lymphocytic leukaemia in The Netherlands. <i>Leukemia Research</i> , 2016, 50, 37-45.	0.8	12
13	Policymaker, Please Consider Your Needs Carefully: Does Outcomes Research in Relapsed or Refractory Multiple Myeloma Reduce Policymaker Uncertainty Regarding Value for Money of Bortezomib?. <i>Value in Health</i> , 2014, 17, 245-253.	0.3	11
14	Cost-effectiveness of Novel Treatment Sequences for Transplant-Ineligible Patients With Multiple Myeloma. <i>JAMA Network Open</i> , 2021, 4, e213497.	5.9	7
15	Cost of health care for paediatric patients with sickle cell disease: An analysis of resource use and costs in a European country. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28588.	1.5	5
16	A population-based study on different regimens of R-CHOP in patients with newly diagnosed DLBCL in The Netherlands. <i>Leukemia and Lymphoma</i> , 2021, 62, 549-559.	1.3	5
17	A Systematic Review of Cost-Effectiveness Analyses of Novel Agents in the Treatment of Multiple Myeloma. <i>Cancers</i> , 2021, 13, 5606.	3.7	5
18	Second-line treatment for acute graft-versus-host disease with mesenchymal stromal cells: A decision model. <i>European Journal of Haematology</i> , 2018, 101, 676-683.	2.2	4

#	ARTICLE	IF	CITATIONS
19	Using Appropriate Methods in Cost-Effectiveness Analyses: The Case of Allogeneic Hematopoietic Cell Transplantation in Sickle Cell Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 2109-2110.	2.0	2
20	Lenalidomide for the Treatment of Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated with Deletion 5q Cytogenetic Abnormality: An Evidence Review of the NICE Submission from Celgene. <i>Pharmacoeconomics</i> , 2016, 34, 23-31.	3.3	2
21	Variation in the utilization of medical devices across Germany, Italy, and the Netherlands: A multilevel approach. <i>Health Economics (United Kingdom)</i> , 2022, 31, 135-156.	1.7	2
22	Medical Resource Use and Medical Costs for Radiotherapy-Related Adverse Effects: A Systematic Review. <i>Cancers</i> , 2022, 14, 2444.	3.7	2
23	Assessment of Studies Evaluating Incremental Costs, Effectiveness, or Cost-Effectiveness of Systemic Therapies in Breast Cancer Based on Claims Data: A Systematic Review. <i>Value in Health</i> , 2020, 23, 1497-1508.	0.3	1
24	Real-world healthcare costs of localized and regionally advanced cutaneous melanoma in the Netherlands. <i>Melanoma Research</i> , 2021, 31, 249-257.	1.2	1
25	Cost-effectiveness of lenalidomide plus rituximab versus rituximab monotherapy in patients with previously treated follicular lymphoma: a societal view. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 1-12.	2.4	1